Drug and Therapy Development for Triple Negative Breast Cancer

by Kendrekar, Pravin; Adimule, Vinayak; Hurst, Tara

• ISBN13: 9783527351756
• ISBN10: 3527351752
• eBook ISBN(s): 9783527841172
• Edition: 1st
• Format: Hardcover
• Copyright: 2023-06-12
• Publisher: Wiley-VCH
• More Book Details
• Purchase Benefits

Summary

Drug and Therapy Development for Triple Negative Breast Cancer

The first comprehensive and up-to-date compilation of modern diagnostic and treatment methods for triple negative breast cancer

In Drug and Therapy Development for Triple Negative Breast Cancer, a team of distinguished practitioners delivers an in-depth and authoritative discussion of contemporary methods for treating triple negative breast cancer (TNBC). The editors have included material that covers its molecular causes, initial detection, diagnostic tools, treatment procedures, pharmacology, and new and experimental therapies—including nanotherapeutics and photothermal therapies.

As the first comprehensive compilation of modern treatment methods for TNBC, this reference is an unmatched source of information about current and future treatment approaches, including machine learning methods for earlier detection and more accurate diagnosis. Readers will also find:

• A thorough introduction to HER receptors in breast cancers
• Comprehensive explorations of the etiology and therapy of hormone receptor-positive breast cancer and the early-stage diagnosis of breast cancer
• Application of artificial intelligence to breast cancer diagnosis
• New insights on the role of DNA replication stress and genome instability in breast cancer

Perfect for medicinal and pharmaceutical chemists, Drug and Therapy Development for Triple Negative Breast Cancer will also benefit oncologists and professionals working in the pharmaceutical industry or in hospital settings.

Author Biography

Pravin Kendrekar works at the School of Natural Sciences in the University of Central Lancashire, Preston, UK.

Vinayak Adimule works at the Angadi Institute of Technology and Management in Belagavi, India.

Tara Hurst works in the School of Health Sciences at Birmingham City University in Edgbaston, UK.

Table of Contents

HISTORY OF BREAST CANCER
Biopharming: an alternative route in the production of anti-cancer protein molecules
Early-Stage Diagnosis of Breast Cancer: Amelioration in Approaches
Understanding Protein nano-assembly based Breast Cancer Therapy

MOLECULAR BIOLOGY OF BREAST CANCER
DNA replication stress and genome instability in breast cancer
The impact of microbiota in breast cancer
The role of HER in breast cancer therapy and targeted drug delivery
Recent Advancement of Nanotherapeutics to Treat Breast Cancer
HER Receptor in Breast Cancer
Human endogenous retroviruses in triple negative breast cancer
Breast cancer progression: Importance of DNA replication licensing proteins

NOVEL DRUG DISCOVERY AND DEVELOPMENT
Development in Drug repurposing for the treatment of Acute Leukemia complicating metastatic breast cancer
Diagnosis, treatment, and prevention of breast cancers using green synthesized nanoparticles

ADVANCED TECHNOLOGIES IN BREAST CANCER THERAPY
Artificial Intelligence-driven Decisions in Breast Cancer Diagnosis
Segmentation Guided Attention based Classification Network for classification of Breast Tumours in Ultrasound images
Establishing nanotechnology-based drug development for triple-negative breast cancer treatment
Etiology and therapy of hormone receptor positive breast cancer
Donor-Acceptor Based Heterocyclic Compounds as Chemo-Photo thermal Agents in Treatment of Breast Cancer

REGULATORY, CLINICAL ASPECTS AND CASE STUDIES
An insight into drug regulatory affairs and the procedures
Recent progress in anticancer drug registrations in USA, Europe and in India